A director at Ryman Healthcare Limited bought 29,361 shares at 4.234NZD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
RYMAN HEALTHCARE (NZ), a company active in the Health Care Providers industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 2 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date April 1, 2022, the closing price was NZD 9.17 and its pot...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad i...
Transition of our coverage to a new analyst and an acceleration in fiscal 2019 build rate prompts a revision in our development and margin forecasts for narrow-moat Ryman Healthcare, but our fair value estimate of NZD 13.00 remains intact. Ryman finished fiscal 2019 in line with consensus, with underlying earnings of NZD 227 million, or NZD 45 cents per share, up 11.5% on fiscal 2018. This was driven by increased development margins, particularly from Nellie Melba, Ryman’s second village in M...
Ryman Healthcare is a well-managed company operating retirement villages in New Zealand and Melbourne. The company stands to benefit from a fast-growing elderly demographic in New Zealand and Melbourne. We expect Ryman Healthcare's business to expand strongly during the five years to 2024, driven by new construction in New Zealand and Australia and from the resale of existing units as a result of portfolio growth. Historically, rising dwelling prices have boosted the funds retirees have to purch...
Transition of our coverage to a new analyst and an acceleration in fiscal 2019 build rate prompts a revision in our development and margin forecasts for narrow-moat Ryman Healthcare, but our fair value estimate of NZD 13.00 remains intact. Ryman finished fiscal 2019 in line with consensus, with underlying earnings of NZD 227 million, or NZD 45 cents per share, up 11.5% on fiscal 2018. This was driven by increased development margins, particularly from Nellie Melba, Ryman’s second village in Me...
The slide in Melbourne dwelling prices continues, as CoreLogic reports a 9.8% decline in the median dwelling price for the year to March 2019, bringing the total decline since the peak to 10.3%. We are not overly concerned by the orderly retracement in dwelling prices as retirement living and aged care are very long-duration businesses. There is a silver lining to falling dwelling prices, as prices for development sites are falling, helping to restore initial development margins on future sites ...
The slide in Melbourne dwelling prices continues, as CoreLogic reports a 9.8% decline in the median dwelling price for the year to March 2019, bringing the total decline since the peak to 10.3%. We are not overly concerned by the orderly retracement in dwelling prices as retirement living and aged care are very long-duration businesses. There is a silver lining to falling dwelling prices, as prices for development sites are falling, helping to restore initial development margins on future sites ...
The slide in Melbourne dwelling prices continues, as CoreLogic reports a 9.8% decline in the median dwelling price for the year to March 2019, bringing the total decline since the peak to 10.3%. We are not overly concerned by the orderly retracement in dwelling prices as retirement living and aged care are very long-duration businesses. There is a silver lining to falling dwelling prices, as prices for development sites are falling, helping to restore initial development margins on future sites ...
Narrow-moat-rated Ryman Healthcare reported first-half fiscal 2019 earnings of NZD 19.3 cents per security and guided to full-year earnings of NZD 44.6 to 47.6 cps. Our forecasts sit in the middle of the guidance range, having been trimmed to NZD 45.8 cps from NZD 46.7 cps to account for rising nurses' wages. We also trimmed the expected profit Ryman makes on newly developed independent living units, or ILU, as dwelling prices in Australia have fallen faster than anticipated, down roughly 10% ov...
Ryman Healthcare is a well-managed company operating retirement villages in New Zealand and Melbourne. The company stands to benefit from a fast-growing elderly demographic in New Zealand and Melbourne. We expect Ryman Healthcare's business to expand strongly during the five years to 2023, driven by new construction in New Zealand and Australia and from the resale of existing units as a result of portfolio growth. Rising dwelling prices have boosted the funds retirees have to purchase retirement...
Narrow-moat-rated Ryman Healthcare reported first-half fiscal 2019 earnings of NZD 19.3 cents per security and guided to full-year earnings of NZD 44.6 to 47.6 cps. Our forecasts sit in the middle of the guidance range, having been trimmed to NZD 45.8 cps from NZD 46.7 cps to account for rising nurses' wages. We also trimmed the expected profit Ryman makes on newly developed independent living units, or ILU, as dwelling prices in Australia have fallen faster than anticipated, down roughly 10% ov...
We have a more upbeat assessment of long-term growth prospects for narrow-moat-rated Ryman Healthcare and have upgraded our fair value estimate to NZD 13.60 from NZD 11.30. Our upgrade follows a revisit of industry drivers for the broader Australian and New Zealand retirement living and aged care sectors. The biggest upgrade relates to the outlook for Ryman's Australian operations, where the firm has just delivered the first phase of its second village, its largest to date, the 580 bed Nellie Me...
Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks...
We have a more upbeat assessment of long-term growth prospects for narrow-moat-rated Ryman Healthcare and have upgraded our fair value estimate to NZD 13.60 from NZD 11.30. Our upgrade follows a revisit of industry drivers for the broader Australian and New Zealand retirement living and aged care sectors. The biggest upgrade relates to the outlook for Ryman's Australian operations, where the firm has just delivered the first phase of its second village, its largest to date, the 580 bed Nellie Me...
We have a more upbeat assessment of long-term growth prospects for narrow-moat-rated Ryman Healthcare and have upgraded our fair value estimate to NZD 13.60 from NZD 11.30. Our upgrade follows a revisit of industry drivers for the broader Australian and New Zealand retirement living and aged care sectors. The biggest upgrade relates to the outlook for Ryman's Australian operations, where the firm has just delivered the first phase of its second village, its largest to date, the 580 bed Nellie Me...
We have a more upbeat assessment of long-term growth prospects for narrow-moat-rated Ryman Healthcare and have upgraded our fair value estimate to NZD 13.60 from NZD 11.30. Our upgrade follows a revisit of industry drivers for the broader Australian and New Zealand retirement living and aged care sectors. The biggest upgrade relates to the outlook for Ryman's Australian operations, where the firm has just delivered the first phase of its second village, its largest to date, the 580 bed Nellie Me...
We have a more upbeat assessment of long-term growth prospects for narrow-moat-rated Ryman Healthcare and have upgraded our fair value estimate to NZD 13.60 from NZD 11.30. Our upgrade follows a revisit of industry drivers for the broader Australian and New Zealand retirement living and aged care sectors. The biggest upgrade relates to the outlook for Ryman's Australian operations, where the firm has just delivered the first phase of its second village, its largest to date, the 580 bed Nellie Me...
Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Se...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.